SCHEMBL4016887

SCHEMBL4016887

CC(=O)c1ccc(Nc2ncc(I)c(NC(O)CC(C)C)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.45
FLT3 P36888 1/20 0.45
EGFR P00533 3/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NPR3 P17342 3/20 0.41
AURKA O14965 2/20 0.41
MAPT P10636 2/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2C8 P10632 1/20 0.40
CCNA2 P20248 4/20 0.39
CDK2 P24941 4/20 0.39
CCNA1 P78396 4/20 0.39
CDK5 Q00535 4/20 0.39
DYRK1A Q13627 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4018350 0.87 AURKA (0.52) CHEK1FLT3EGFRNPC1RAB9A
SCHEMBL4020090 0.83 CDK1 (0.58) CCNA2CDK2CCNA1SYK
SCHEMBL4016880 0.83 CHEK1 (0.45) CHEK1FLT3EGFRNPC1RAB9A
SCHEMBL5169528 0.83 CHEK1 (0.45) CHEK1FLT3EGFRNPC1RAB9A
SCHEMBL4026166 0.76 CDK1 (0.51) CHEK1FLT3EGFRNPC1RAB9A
SCHEMBL13648454 0.70 NPC1 (0.48) CHEK1FLT3EGFRNPC1RAB9A
SCHEMBL4017023 0.70 CDK2 (0.58) AURKACCNA2CDK2CCNA1CDK5
SCHEMBL13648519 0.70 CDK1 (0.57) CHEK1CDK2
SCHEMBL5173644 0.70 AURKA (0.52) CHEK1FLT3NPC1RAB9AAURKA
SCHEMBL13648652 0.70 CDK1 (0.57) CHEK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598260-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-06 US disclosed
US-20080039447-A1 CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents BRUMBY THOMAS 2008-02-14 US disclosed
US-7291624-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2007-11-06 US disclosed
US-7235561-B2 Compound and a composition including such a compound SCHERING AG (DE) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039447-A1 CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents CDK2, CDK1, CDK6 CHEK1 76/4885FLT3 403/4885EGFR 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.